https://doi.org/10.4081/reumatismo.2025.1694
Real-world clinical experience with secukinumab in psoriatic arthritis: an observational study and a literature review
Submitted: 21 December 2023
Accepted: 11 July 2024
Published: 27 January 2025
Accepted: 11 July 2024
Abstract Views: 227
PDF: 97
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Objective. Psoriatic arthritis (PsA) can be treated with biological drugs targeting IL-17A, such as secukinumab, with good responses and long-term positive outcomes in clinical studies.
Methods. An observational study was conducted on adult subjects with PsA and comorbidities, treated with secukinumab after prior therapy with conventional disease-modifying anti-rheumatic drugs or biological agents that were discontinued due to lack of efficacy or adverse drug reactions. Patients were followed up with clinical visits at 3, 6, 9, and 12 months and evaluated for disease activity, pain, and quality of life, with respect to values recorded at baseline. Moreover, a narrative review of the literature was performed on secukinumab’s use for PsA in real life.
Results. Fifteen patients completed 6 months of follow-up, eleven patients completed 9 months, and six patients were followed for 12 months. The major comorbidities recorded were fibromyalgia (33% of patients), recurrent bilateral anterior uveitis, and autoimmune thyroiditis with hypothyroidism (both 13% of the patients). A significant improvement in Disease Activity Score-28 was recorded at 6 and 9 months, while a significant difference vs. baseline was seen at 3, 6, and 9 months for the Psoriasis Area Severity Index. The Bath Ankylosing Spondylitis Disease Activity Index showed significant differences vs. baseline at 9 and 12 months. There was an improving trend at 9 and 12 months for pain scores and a significant improvement at 6 and 9 months for the physical component and at 12 months for the social component (Short Form 36 Health Survey quality of life scores). For the review of the literature, 35 articles were identified but only 17 papers were eventually considered.
Conclusions. Secukinumab has demonstrated effectiveness for PsA treatment in several real-world studies. Both patient-oriented and clinician-oriented outcomes showed a significant improvement with this treatment. The present real-world evaluation adds further evidence of the use of secukinumab for PsA treatment, showing the rapid, safe, clinically significant, and sustained responses of PsA patients affected by co-morbidities.
Van den Bosch F, Coates L. Clinical management of psoriatic arthritis. Lancet 2018; 391: 2285-94.
DOI: https://doi.org/10.1016/S0140-6736(18)30949-8
Ocampo DV, Gladman D. Psoriatic arthritis. F1000Res 2019;8: F1000 Faculty Rev-1665.
DOI: https://doi.org/10.12688/f1000research.19144.1
Husni ME. Comorbidities in psoriatic arthritis. Rheum Dis Clin North Am 2015; 41: 677-98.
DOI: https://doi.org/10.1016/j.rdc.2015.07.008
Silvagni E, Bortoluzzi A, Ciancio G, Govoni M. Biological and synthetic target DMARDs in psoriatic arthritis. Pharmacol Res 2019; 149: 104473.
DOI: https://doi.org/10.1016/j.phrs.2019.104473
Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol 2018; 55: 379-90.
DOI: https://doi.org/10.1007/s12016-018-8702-3
Sakkas LI, Zafiriou E, Bogdanos DP. Mini review: new treatments in psoriatic arthritis. Focus on the IL-23/17 axis. Front Pharmacol 2019; 10: 872.
DOI: https://doi.org/10.3389/fphar.2019.00872
Speeckaert R, van Geel N, Lambert J, Claeys L, Delanghe JR, Speeckaert MM. Secukinumab: IL-17A inhibition to treat psoriatic arthritis. Drugs Today 2016; 52: 607-16.
DOI: https://doi.org/10.1358/dot.2016.52.11.2526754
Reich K, Warren RB, Coates LC, Di Comite G. Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease. J Eur Acad Dermatol Venereol 2020; 34: 1161-73.
DOI: https://doi.org/10.1111/jdv.16124
McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015; 386: 1137-46.
DOI: https://doi.org/10.1016/S0140-6736(15)61134-5
McInnes IB, Mease PJ, Ritchlin CT, Rahman P, Gottlieb AB, Kirkham B, et al. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. Rheumatology 2017; 56: 1993-2003.
DOI: https://doi.org/10.1093/rheumatology/kex301
Mease P, van der Heijde D, Landewe R, Mpofu S, Rahman P, Tahir H, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis 2018; 77: 890-7.
DOI: https://doi.org/10.1136/annrheumdis-2017-212687
Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med 2015; 373: 1329-39.
DOI: https://doi.org/10.1056/NEJMoa1412679
van der Heijde D, Mease PJ, Landewe RBM, Rahman P, Tahir H, Singhal A, et al. Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5. Rheumatology 2020; 59: 1325-34..
DOI: https://doi.org/10.1093/rheumatology/kez420
Bartlett VL, Dhruva SS, Shah nd, ryan p, ross js. feasibility of Using Real-World Data to Replicate Clinical Trial Evidence. JAMA Netw Open 2019; 2: e1912869.
DOI: https://doi.org/10.1001/jamanetworkopen.2019.12869
Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973; 3: 55-78.
DOI: https://doi.org/10.1016/0049-0172(73)90035-8
Moreno-Ramos MJ, Sanchez-Piedra C, Martinez-Gonzalez O, Rodriguez-Lozano C, Perez-Garcia C, Freire M, et al. Real-world effectiveness and treatment retention of secukinumab in patients with psoriatic arthritis and axial spondyloarthritis: a descriptive observational analysis of the Spanish BIOBADASER registry. Rheumatol Ther 2022; 9: 1031-47.
DOI: https://doi.org/10.1007/s40744-022-00446-9
Kiltz U, Sfikakis PP, Gaffney K, Sator PG, von Kiedrowski R, Bounas A, et al. Secukinumab use in patients with moderate to severe psoriasis, psoriatic arthritis and ankylosing spondylitis in real-world setting in Europe: baseline data from SERENA study. Adv Ther 2020; 37: 2865-83.
DOI: https://doi.org/10.1007/s12325-020-01352-8
Elliott A, Wright G. Real-world data on secukinumab use for psoriatic arthritis and ankylosing spondylitis. Ther Adv Musculoskelet Dis 2019; 11: 1759720X19858510.
DOI: https://doi.org/10.1177/1759720X19858510
Klavdianou K, Lazarini A, Grivas A, Tseronis D, Tsalapaki C, Rapsomaniki P, et al. Real life efficacy and safety of secukinumab in biologic-experienced patients with psoriatic arthritis. Front Med 2020; 7: 288.
DOI: https://doi.org/10.3389/fmed.2020.00288
Fujita H, Ohtsuki M, Morita A, Nagao R, Seko N, Matsumoto K, et al. Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: real-world evidence in Japan. J Dermatol 2021; 48: 175-83.
DOI: https://doi.org/10.1111/1346-8138.15655
Geale K, Lindberg I, Paulsson EC, Wennerstrom ECM, Tjarnlund A, Noel W, et al. Persistence of biologic treatments in psoriatic arthritis: a population-based study in Sweden. Rheumatol Adv Pract 2020; 4: rkaa070.
DOI: https://doi.org/10.1093/rap/rkaa070
Dauden E, de Lima GPG, Armesto S, Herrera-Acosta E, Vidal D, Villarasa E, et al. Multicenter retrospective study of secukinumab drug survival in psoriasis patients in a daily practice setting: a long-term experience in Spain. Dermatol Ther 2021; 11: 2207-15.
DOI: https://doi.org/10.1007/s13555-021-00606-9
Eviatar T, Zisman D, Gendelman O, Reitblat T, Balbir-Gurman A, Mashiach T, et al. Secukinumab real world drug retention compared to TNF-alpha inhibitors in psoriatic arthritis. Clin Exp Rheumatol 2022; 40: 15-23.
DOI: https://doi.org/10.55563/clinexprheumatol/1sx5yk
Valero-Exposito M, Martin-Lopez M, Guillen-Astete C, Joven B, Merino-Argumanez C, Emperiale V, et al. Retention rate of secukinumab in psoriatic arthritis: real-world data results from a Spanish multicenter cohort. Medicine 2022; 101: e30444.
DOI: https://doi.org/10.1097/MD.0000000000030444
Moskal M, Krawiec P, Zareba W, Swierczek I, Ratusznik J, Raputa W, et al. Drug retention and safety of secukinumab in a real-world cohort of ankylosing spondylitis and psoriatic arthritis patients. Int J Environ Res Public Health 2022; 19: 15861.
DOI: https://doi.org/10.3390/ijerph192315861
Garcia-Dorta A, Leon-Suarez P, Pena S, Hernandez-Diaz M, Rodriguez-Lozano C, Gonzalez-Davila E, et al. Association of gender, diagnosis, and obesity with retention rate of secukinumab in spondyloarthropathies: results form a multicenter real-world study. Front Med 2021; 8: 815881.
DOI: https://doi.org/10.3389/fmed.2021.815881
Gaffney K, Gullick N, MacKay K, Patel Y, Sengupta R, Sheeran T, et al. Real-world evidence for secukinumab in UK patients with psoriatic arthritis or radiographic axial spondyloarthritis: interim 2-year analysis from SERENA. Rheumatol Adv Pract 2023; 7: rkad055.
DOI: https://doi.org/10.1093/rap/rkad055
Kiltz U, Sfikakis PP, Gaffney K, Bounas A, Gullick N, Lespessailles E, et al. Interim 2-year analysis from SERENA: a real-world study in patients with psoriatic arthritis or ankylosing spondylitis treated with secukinumab. Rheumatol Ther 2022; 9: 1129-42.
DOI: https://doi.org/10.1007/s40744-022-00460-x
Michelsen B, Georgiadis S, Di Giuseppe D, Loft AG, Nissen MJ, Iannone F, et al. Real-world six- and twelve-month drug retention, remission, and response rates of secukinumab in 2,017 patients with psoriatic arthritis in thirteen European countries. Arthritis Care Res 2022; 74: 1205-18.
DOI: https://doi.org/10.1002/acr.24560
Colombo D, Frassi M, Pagano Mariano G, Fusaro E, Lomater C, Del Medico P, et al. Real-world evidence of biologic treatments in psoriatic arthritis in Italy: results of the CHRONOS (EffeCtiveness of biologic treatments for psoriatic artHRitis in Italy: an ObservatioNal lOngitudinal Study of real-life clinical practice) observational longitudinal study. BMC Rheumatol 2022; 6: 57.
DOI: https://doi.org/10.1186/s41927-022-00284-w
Mease PJ, Blachley T, Dube B, McLean RR, Kim N, Hur P, et al. Effectiveness of 6-month use of secukinumab in patients with psoriatic arthritis in the CorEvitas psoriatic arthritis/spondyloarthritis registry. J Rheumatol 2022; 49: 700-6.
DOI: https://doi.org/10.3899/jrheum.211033
Magrey M, Bozyczko M, Wolin D, Mordin M, McLeod L, Davenport E, et al. Evaluation of the feasibility of a web-based survey to assess patient-reported symptom improvement and treatment satisfaction among patients with psoriatic arthritis receiving secukinumab. Clin Drug Investig 2019; 39: 1205-12.
DOI: https://doi.org/10.1007/s40261-019-00856-8
Nicola S, Rolla G, Monti R, Brussino L. Treatment of psoriatic arthritis with secukinumab: a case series. J Dermatolog Treat 2018; 29: 6-8.
DOI: https://doi.org/10.1080/09546634.2018.1527994
Pinto Tasende JA, Maceiras Pan FJ, Mosquera Martinez JA, Fernandez Dominguez L, Correa Rey B, Garcia Porrua C. Secukinumab as biological treatment for psoriatic arthritis in real clinical practice. Reumatol Clin 2021; 17: 203-6.
DOI: https://doi.org/10.1016/j.reumae.2020.02.002
Chiricozzi A, Balato A, Conrad C, Conti A, Dapavo P, Ferreira P, et al. Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study. J Dermatolog Treat 2020;31:476-83.
DOI: https://doi.org/10.1080/09546634.2019.1671577
Alegre-Sancho JJ, Nunez-Monje V, Campos-Fernandez C, Balaguer-Trull I, Robustillo-Villarino M, Aguilar-Zamora M, et al. Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis. Front Med 2023; 10: 1294247.
DOI: https://doi.org/10.3389/fmed.2023.1294247
How to Cite
Celletti, E., Gualdi, G., Sabatini, E., Cipollone, F., Lobefaro, F., & Amerio, P. (2025). Real-world clinical experience with secukinumab in psoriatic arthritis: an observational study and a literature review. Reumatismo. https://doi.org/10.4081/reumatismo.2025.1694
Copyright (c) 2025 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Similar Articles
- G.D. Sebastiani, Antineutrophil cytoplasmic antibodies , Reumatismo: Vol. 61 No. 1 (2009)
- R. Herrera-Esparza, E. Avalos-Diaz, Infliximab treatment in a case of rheumatoid scleromalacia perforans , Reumatismo: Vol. 61 No. 3 (2009)
- D. Buskila, J. Ablin, Pediatric fibromyalgia , Reumatismo: Vol. 64 No. 4 (2012)
- A. Volpe, A. Angheben, A. Marchetta, P. Caramaschi, D. Biasi, A. Carletto, S. Marocco, G. Monteiro, L.M. Bambara, G. Arcaro, Z. Bisoffi, Chikungunya arthritis: report of 6 cases , Reumatismo: Vol. 60 No. 2 (2008)
- M. E. Tezcan, Ş. Demir, M. Sargın, M. Aliustaoğlu, B. Göker, Sjögren’s syndrome and mean platelet volume , Reumatismo: Vol. 67 No. 1 (2015)
- G. Pasero, P. Marson, B. Gatto, A short history of anti-rheumatic therapy - VII. Biological agents , Reumatismo: Vol. 63 No. 3 (2011)
- G. Di Comite, G. Bonavida, E. Bozzolo, S. Bozzolo, S. Bianchi, G. Ciboddo, M. Tresoldi, L. Praderio, M.G. Sabbadini, Wegener’s granulomatosis: an analysis of 50 patients , Reumatismo: Vol. 57 No. 3 (2005)
- V.F. Azevedo, C.F. Pietrovski, M. de Almeida Santos Jr, Acute toxoplasmosis infection in a patient with ankylosing spondylitis treated with adalimumab: a case report , Reumatismo: Vol. 62 No. 4 (2010)
- M. Fabris, L. Quartuccio, S. Lombardi, M. Benucci, M. Manfredi, M. Saracco, F. Atzeni, P. Morassi, M.A. Cimmino, E. Pontarini, C. Fabro, R. Pellerito, P. Sarzi-Puttini, M. Cutolo, A. Carletto, L.M. Bambara, F. Fischetti, F. Curcio, E. Tonutti, S. De VIta, Study on the possible role of the -174G>C IL-6 promoter polymorphism in predicting response to rituximab in rheumatoid arthritis , Reumatismo: Vol. 62 No. 4 (2010)
- P. Sarzi- Puttini, F. Atzeni, L. Lanata, M. Bagnasco, M. Colombo, F. Fischer, M. D'Imporzano, Pain and ketoprofen: what is its role in clinical practice? , Reumatismo: Vol. 62 No. 3 (2010)
<< < 34 35 36 37 38 39 40 41 42 43 > >>
You may also start an advanced similarity search for this article.
